<DOC>
	<DOCNO>NCT00002703</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high energy x-rays damage tumor cell . PURPOSE : Randomized phase III trial compare effectiveness conventional radiation therapy high-dose radiation therapy treat men stage I stage II prostate cancer .</brief_summary>
	<brief_title>Radiation Therapy Treating Patients With Stage I Stage II Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether high-dose radiotherapy use conformal photon proton boost produce 20 % increase proportion Stage I/II prostate cancer free local failure biochemical relapse 5 year compare result conventional-dose radiotherapy . II . Determine whether high-dose radiotherapy produce 33 % reduction cumulative incidence rise PSA ( second hormone failure ) follow hormone therapy give time first PSA/clinical failure compare conventional-dose radiotherapy . IV . Assess relative rectal , bladder , sexual morbidity conformal photon dose 70.2 79.2 Gy patient . V. Collect , prospective manner , paraffin biopsy block subsequent analysis emerge molecular pathologic predictor outcome three patient . OUTLINE : Randomized study . Arm I : Radiotherapy . Boost prostate use high-LET proton follow irradiation prostate , periprostatic tissue , seminal vesicle use conformal photon energy great 6 MV . Conventional dose . Arm II : Radiotherapy . As Arm I . High dose . PROJECTED ACCRUAL : There 390 patient accrue study 3 year . An additional 3.5 year require follow-up .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Primary tumor confine prostate TNM clinical Stages T1bc T2ab No T1a No T1bc tumor Gleason grade 12/5 No Gleason grade 12/5 PSA less 4 ng/mL Nodes negative imaging ( Nx ) surgical sampling ( N0 ) PSA great 15 ng/mL Treatment must begin within 28 day randomization PATIENT CHARACTERISTICS : Age : Any age Performance status : Karnofsky 70 % 100 % Life expectancy : Greater 10 year Other : No major medical psychiatric illness precludes protocol entry No prior concurrent second malignancy within 5 year except basal cell skin cancer PRIOR CONCURRENT THERAPY : No prior treatment prostate cancer</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
</DOC>